ArticleMolecular cancer research : MCR2007
Reprogramming leukemia cells to terminal differentiation and growth arrest by RNA interference of PU.1.
Article in Molecular cancer research : MCR, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- The histone methyltransferase inhibitor A-366 enhances hemoglobin expression in erythroleukemia cells upon co-exposure with chemical inducers in culture.Journal of biological research (Thessalonike, Greece) · 2021Article
- Fli-1 overexpression in erythroleukemic cells promotes erythroid de-differentiation while Spi-1/PU.1 exerts the opposite effect.International journal of oncology · 2017Article
- Mathematical modeling of GATA-switching for regulating the differentiation of hematopoietic stem cell.BMC systems biology · 2014Article
- DNA methylation-mediated silencing of PU.1 in leukemia cells resistant to cell differentiation.SpringerPlus · 2013Article
- Article
- Mybl2, downregulated during colon epithelial cell maturation, is suppressed by miR-365.American journal of physiology. Gastrointestinal and liver physiology · 2011Article
- MYBL2, a link between proliferation and differentiation in maturing colon epithelial cells.Journal of cellular physiology · 2011Article
- PU.1 and Haematopoietic Cell Fate: Dosage Matters.International journal of cell biology · 2011Article
- The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis.Leukemia · 2010Review
- PU.1 directly regulates cdk6 gene expression, linking the cell proliferation and differentiation programs in erythroid cells.The Journal of biological chemistry · 2010Article
- PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.Molecular cancer research : MCR · 2009Article
- Stat3 promotes the development of erythroleukemia by inducing Pu.1 expression and inhibiting erythroid differentiation.Oncogene · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Malignant transformation often leads to both loss of normal proliferation control and inhibition of cell differentiation. Some tumor cells can be stimulated to reenter their differentiation program and to undergo terminal growth arrest. The in vitro differentiation of mouse erythroleukemia (MEL) cells is an important example of tumor cell reprogramming. MEL cells are malignant erythroblasts that are blocked from differentiating into mature RBC due to dysregulated expression of the transcription factor PU.1, which binds to and represses GATA-1, the major transcriptional regulator of erythropoiesis. We used RNA interference to ask whether inhibiting PU.1 synthesis was sufficient to cause MEL cells to lose their malignant properties. We report here that transfection of MEL cells with a PU.1-specific short interfering RNA oligonucleotide causes the cells to resume erythroid differentiation, accumulate hemoglobin, and undergo terminal growth arrest. RNA interference directed at specific, aberrantly expressed transcription factors may hold promise for the development of potent antitumor therapies in other hematologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.